Record Display for the EPA National Library Catalog


Main Title Comparison of In vitro and In vivo Methods for Evaluating Alterations in Hepatic Drug Metabolism Following Mercuric Chloride Administration.
Author Trela, B. A. ; Carlson, G. P. ; Chadwick, R. W. ; Copeland, M. F. ;
CORP Author Health Effects Research Lab., Research Triangle Park, NC. ;Purdue Univ., Lafayette, IN. School of Pharmacy and Pharmacal Sciences.
Year Published 1986
Report Number EPA/600/J-86/361;
Stock Number PB87-194536
Additional Subjects Liver ; Toxicology ; Pathology ; Rats ; Chlorobenzenes ; Reprints ; Mercuric chloride ; Nephrotic syndrome ; Mixed function oxidases
Library Call Number Additional Info Location Last
NTIS  PB87-194536 Some EPA libraries have a fiche copy filed under the call number shown. 07/26/2022
Collation 11p
Mercuric chloride was administered once ip to female Fischer 344 rats at doses of 0, 0.2, 0.6, and 1.8 mg/kg. Although there were no alterations in the urinary excretion of lactate dehydrogenase, significant elevations in the activities of urinary alkaline phosphatase, glutamicpyruvic transaminase and glutamicoxalacetic transaminase indicated that mercuric chloride was nephrotoxic. There was no evidence of hepatotoxicity as hepatic glucose-6-phosphatase and serum sorbitol dehydrogenase were essentially unaffected by mercuric chloride administration. Of the four phase II reactions measured, only the glucuronidation of chloramphenicol was diminished by treatment with mercuric chloride. Results from the in vivo studies on the metabolism of lindane, which indicated no change in the excretion of free or conjugated metabolites, were in close agreement with the in vitro data suggesting that the nephrotoxic effects of mercuric chloride do not alter the urinary excretion of the model substrate lindane.